JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

Strona główna・Stock List・Ultragenyx Pharmaceutical Inc

Ultragenyx Pharmaceutical Inc

Closed

SectorHealthcare

24.75 0.32

Buy Sell

Overview

Share price change

24h

Current

Min

24.66

Max

24.81

Key metrics
By Trading Economics
Income	51M -129M
Sales	207M
Profit margin	-62.319
Employees	1,371
EBITDA	8.8M -105M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+111.71% upside

Dividends
By Dow Jones
Next Earnings	5 maj 2026

Market Stats
By TradingEconomics
Market Cap	379M 2.4B
Previous open	24.43
Previous close	24.75

News Sentiment

By Acuity

19%

81%

35 / 347 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

32.76 / 39.24 Support & Resistance

Ultragenyx Pharmaceutical Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

1 maj 2026, 21:36 UTC

Acquisitions, Mergers, Takeovers

FTC Requires 365 Retail Markets to Divest Micromarket Kiosk Business to Clear Acquisition of Cantaloupe

1 maj 2026, 20:40 UTC

Acquisitions, Mergers, Takeovers

Meta Platforms Acquires Humanoid Robot Startup Assured Robot Intelligence

1 maj 2026, 18:37 UTC

Major Market Movers

Senseonic Shares Slide on Underwritten Offering Price

1 maj 2026, 16:46 UTC

Major Market Movers

Stellantis, Ferrari Fall on Trump Plan to Increase Tariff on European Cars, Trucks

2 maj 2026, 19:57 UTC

Acquisitions, Mergers, Takeovers

Berkshire CEO Greg Abel Takes the Stage, Making a Case for the Post-Buffett Era -- 3rd Update

2 maj 2026, 15:24 UTC

Earnings

Berkshire CEO Greg Abel Takes the Stage, Talks Through Quarterly Results -- Update

2 maj 2026, 12:46 UTC

Earnings

Acquisitions, Mergers, Takeovers

Berkshire Profits More Than Double on Gains in Insurance, Railroad, Energy Businesses -- WSJ

2 maj 2026, 08:20 UTC

Market Talk

Financial Services Roundup: Market Talk

1 maj 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

1 maj 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

1 maj 2026, 20:42 UTC

Earnings

Western Digital Beats Earnings Estimates. The Stock Is Falling Anyway. -- Barrons.com

1 maj 2026, 19:33 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

1 maj 2026, 19:33 UTC

Market Talk

Change in Fed Leadership May Hamper Crypto Rebound -- Market Talk

1 maj 2026, 19:18 UTC

Market Talk

Major News Events

Oil Rises for Second Consecutive Week Amid Middle East Standoff -- Market Talk

1 maj 2026, 19:13 UTC

Market Talk

Natural Gas Rises as Markets Wait for Warmer Temperatures -- Market Talk

1 maj 2026, 18:36 UTC

Earnings

3 Takeaways From Apple Earnings. The Stock Is Surging. -- Barrons.com

1 maj 2026, 18:35 UTC

Earnings

Moderna's Covid Vaccine Is Driving Growth Again. The Stock Is Down Anyway. -- Barrons.com

1 maj 2026, 18:28 UTC

Earnings

These Stocks Are Today's Movers: Apple, Sandisk, Roblox, Intel, Ferrari, Atlassian, Western Digital, Clorox, Paramount Skydance, and More -- Barrons.com

1 maj 2026, 18:27 UTC

Market Talk

Gold and Silver Higher for the Day, Lower For The Week -- Market Talk

1 maj 2026, 18:14 UTC

Acquisitions, Mergers, Takeovers

Barclays Completes Acquisition of Best Egg

1 maj 2026, 18:04 UTC

Earnings

The First $6 Trillion Company May Not Be Nvidia -- Barrons.com

1 maj 2026, 17:43 UTC

Market Talk

Home Sales in San Francisco Jump 22.2% in March -- Market Talk

1 maj 2026, 17:37 UTC

Market Talk

Crypto 'Fear and Greed Index' Returns to Neutral Reading After Brief Dip -- Market Talk

1 maj 2026, 17:30 UTC

Market Talk

Earnings

Apple's 2Q Print, 3Q Guide Set Up Stock to Outperform -- Market Talk

1 maj 2026, 17:28 UTC

Market Talk

Earnings

Apple's Shift From Net Cash Neutral Goal Seen as Cryptic Signal -- Market Talk

1 maj 2026, 17:21 UTC

Market Talk

Earnings

Apple Seen Absorbing Higher Memory Costs -- Market Talk

1 maj 2026, 17:19 UTC

Market Talk

Major News Events

U.S. Oil Rig Count Rises by 1 to 408 -- Market Talk

1 maj 2026, 16:38 UTC

Market Talk

Institutional Markets Begin to Trade on Event Contracts -- Market Talk

1 maj 2026, 16:23 UTC

Acquisitions, Mergers, Takeovers

Paramount Skydance Gets a Double Upgrade. It's the Warner Bros. Deal. -- Barrons.com

1 maj 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

Peer Comparison

Price change

Ultragenyx Pharmaceutical Inc Forecast

Price Target

By TipRanks

111.71% upside

12 Months Forecast

Average 52.44 USD 111.71%

High 84 USD

Low 25 USD

Based on 18 Wall Street analysts offering 12 month price targets forUltragenyx Pharmaceutical Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

18 ratings

Buy

Hold

Sell

Based on 18 analysts giving stock ratings to Ultragenyx Pharmaceutical Inc - Dist in the past 3 months.

Technical Score

By Trading Central

32.76 / 39.24Support & Resistance

Recent bearish events outweigh bullish events.

All events are bearish.

Sentiment

By Acuity

35 / 347 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Ultragenyx Pharmaceutical Inc

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.